Brief Description

FR180204 is a potent and selective ATP-competitive inhibitor of ERK1 and ERK2 with Ki value of 0.31 uM and 0.14 uM respectively; has IC50 values of 0.51 and 0.33 μM in enzymatic assays against ERK1 and ERK2, respectively.
IC50 value: 0.31 uM/0.14 uM(Ki for ERK1/ERK2); 0.51uM/0.33 μM(ERK1/ERK2)
Target: ERK1/2 inhibitor
in vitro: FR180204 inhibited the kinase activity of ERK1 and ERK2, with K(i) values 0.31 and 0.14microM, respectively. Lineweaver-Burk analysis of the binding interaction revealed that FR180204 acted as competitive inhibitor of ATP. In mink lung epithelial Mv1Lu cells, FR180204 inhibited TGFbeta-induced luciferase-expression. Discovered by Ohori and co-workers, it has IC50 values of 0.51 and 0.33 μM in enzymatic assays against ERK1 and ERK2, respectively. It was also shown to inhibit TGFβ-induced AP-1 activation with an IC50 of 3.1 μM in a cellular assay.
in vivo: Preventive administration of FR180204 (100 mg/kg, i.p., b.i.d.) significantly ameliorated the clinical arthritis and body weight loss occurring in the CIA mice. Further, FR180204-treated mice showed a significant decrease in plasma anti-CII antibody levels (62%). FR180204 also attenuated delayed-type hypersensitivity in CII-immunized DBA/1 mice, an inflammatory response elicited by CII-reactive T cells, in a dose-dependent manner (52 and 62% inhibition at 32 and 100 mg/kg, respectively). Moreover, FR180204 inhibited in vitro CII-induced proliferation of lymph node cells prepared from CII-immunized mice, in which CII-specific T cells are known to undergo specific proliferation.

Solubility

100 mM in DMSO

Melting point

Boiling point

Density

Formula Weight:

Flash point

Storage conditions

Store at -20°C 2 years

Appearance: